Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5914)
All Articles published online
|
Publishing Process of This Article
|
Aug 7, 2019 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bouché O, Ben Abdelghani M, Labourey JL, Triby S, Bensadoun RJ, Jouary T, Des Guetz G. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer. World J Gastroenterol 2019; 25(29): 4007-4018 [PMID: 31413534 DOI: 10.3748/wjg.v25.i29.4007] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v25/i29/4007.htm |
| Number | Citing Articles |
| 1 |
Paolo Antonetti, Maria Concetta Fargnoli, Giampiero Porzio, Lisa Salvatore, Roberto Filippi, Michele Ghidini, Olga Nigro, Fabio Gelsomino, Ina Valeria Zurlo, Emanuela Dell’Aquila, Pasquale Lombardi, Susana Roselló Keränen, Ilaria Depetris, Riccardo Giampieri, Cristina Morelli, Michele De Tursi, Francesca Romana Di Pietro, Nicoletta Zanaletti, Pasquale Vitale, Ingrid Garajova, Gian Paolo Spinelli, Federica Zoratto, Michela Roberto, Angelica Petrillo, Giacomo Aimar, Alessio Cortellini, Maria Vittoria Pensieri, Corrado Ficorella, Claudio Ferri, Alessandro Parisi. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. Supportive Care in Cancer 2022; 30(3): 2455 doi: 10.1007/s00520-021-06652-5
|
| 2 |
Valencia Long, Ellie Ci-En Choi, Chris Lixian Tan. Supportive oncodermatology—a narrative review of its utility and the way forward. Supportive Care in Cancer 2021; 29(9): 4931 doi: 10.1007/s00520-021-06124-w
|
| 3 |
Elena Muraro, Giuseppe Fanetti, Valentina Lupato, Vittorio Giacomarra, Agostino Steffan, Carlo Gobitti, Emanuela Vaccher, Giovanni Franchin. Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance. Critical Reviews in Oncology/Hematology 2021; 164: 103424 doi: 10.1016/j.critrevonc.2021.103424
|
| 4 |
Wahyuni Wahyuni, Ajeng Diantini, Mohammad Ghozali, Sahidin I. A Review of Current treatment for Triple-Negative Breast Cancer (TNBC). Research Journal of Pharmacy and Technology 2022; : 409 doi: 10.52711/0974-360X.2022.00068
|
| 5 |
Munenobu Kashiwa, Ryo Matsushita. Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan. Journal of Pharmaceutical Health Care and Sciences 2021; 7(1) doi: 10.1186/s40780-021-00218-7
|
| 6 |
Yanhong Yao, Zhentao Liu, Hua Zhang, Jian Li, Zhi Peng, Jinyu Yu, Baoshan Cao, Lin Shen. Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.754858
|
| 7 |
Annika Belzer, Jolanta J. Pach, Kailyn Valido, Jonathan S. Leventhal. The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature. American Journal of Clinical Dermatology 2024; doi: 10.1007/s40257-024-00847-2
|
| 8 |
S. Watanabe, H. Yoshioka, H. Sakai, K. Hotta, M. Takenoyama, K. Yamada, S. Sugawara, Y. Takiguchi, Y. Hosomi, K. Tomii, S. Niho, M. Nishio, T. Kato, T. Takahashi, H. Ebi, M. Aono, N. Yamamoto, Y. Ohe, K. Nakagawa. Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM. ESMO Open 2024; 9(4): 102975 doi: 10.1016/j.esmoop.2024.102975
|
| 9 |
Michael Joseph Lavery, Leigh Forsyth, Elaine Hindle. Cutaneous manifestations secondary to panitumumab therapy. Clinics in Dermatology 2021; 39(5): 887 doi: 10.1016/j.clindermatol.2021.07.014
|